JP2002536318A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002536318A5 JP2002536318A5 JP2000596913A JP2000596913A JP2002536318A5 JP 2002536318 A5 JP2002536318 A5 JP 2002536318A5 JP 2000596913 A JP2000596913 A JP 2000596913A JP 2000596913 A JP2000596913 A JP 2000596913A JP 2002536318 A5 JP2002536318 A5 JP 2002536318A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- polymer
- neutral
- methacrylate
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000642 polymer Polymers 0.000 description 22
- 230000007935 neutral effect Effects 0.000 description 18
- 239000000203 mixture Substances 0.000 description 14
- 229920001577 copolymer Polymers 0.000 description 11
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- -1 dialkylaminoalkyl modified methacrylate Chemical class 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229920001477 hydrophilic polymer Polymers 0.000 description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 3
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 229920003149 Eudragit® E 100 Polymers 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 229940028937 divalproex sodium Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000007580 dry-mixing Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000004513 sizing Methods 0.000 description 2
- 229960000604 valproic acid Drugs 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- 229920003118 cationic copolymer Polymers 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24467899A | 1999-02-04 | 1999-02-04 | |
| US09/244,678 | 1999-02-04 | ||
| PCT/US2000/001954 WO2000045793A1 (en) | 1999-02-04 | 2000-01-26 | Ph independent extended release pharmaceutical formulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011116089A Division JP5420590B2 (ja) | 1999-02-04 | 2011-05-24 | ｐＨ非依存延長放出性医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002536318A JP2002536318A (ja) | 2002-10-29 |
| JP2002536318A5 true JP2002536318A5 (enExample) | 2013-11-14 |
| JP5420126B2 JP5420126B2 (ja) | 2014-02-19 |
Family
ID=22923698
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000596913A Expired - Lifetime JP5420126B2 (ja) | 1999-02-04 | 2000-01-26 | ｐＨ非依存延長放出性医薬組成物 |
| JP2011116089A Expired - Lifetime JP5420590B2 (ja) | 1999-02-04 | 2011-05-24 | ｐＨ非依存延長放出性医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011116089A Expired - Lifetime JP5420590B2 (ja) | 1999-02-04 | 2011-05-24 | ｐＨ非依存延長放出性医薬組成物 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1146864B1 (enExample) |
| JP (2) | JP5420126B2 (enExample) |
| AT (1) | ATE424191T1 (enExample) |
| CA (1) | CA2361496C (enExample) |
| CY (1) | CY1108863T1 (enExample) |
| DE (1) | DE60041691D1 (enExample) |
| DK (1) | DK1146864T3 (enExample) |
| ES (1) | ES2321908T3 (enExample) |
| PT (1) | PT1146864E (enExample) |
| WO (1) | WO2000045793A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020025341A1 (en) * | 1998-12-18 | 2002-02-28 | Yihong Qiu | Controlled release formulation of divalproex sodium |
| US6528090B2 (en) | 1998-12-18 | 2003-03-04 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
| US6713086B2 (en) | 1998-12-18 | 2004-03-30 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
| US6511678B2 (en) | 1998-12-18 | 2003-01-28 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
| US6419953B1 (en) | 1998-12-18 | 2002-07-16 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
| WO2002051402A1 (en) * | 2000-12-22 | 2002-07-04 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
| GB0102342D0 (en) * | 2001-01-30 | 2001-03-14 | Smithkline Beecham Plc | Pharmaceutical formulation |
| WO2004071421A2 (en) * | 2003-02-05 | 2004-08-26 | Teva Pharmaceutical Industries Ltd. | Sustained release formulation of n-(2-propylpentanoyl) glycinamide and related compounds |
| EP1898886B1 (en) | 2005-07-01 | 2019-09-04 | Rubicon Research Pvt Ltd. | Novel sustained release dosage form |
| MX2011011459A (es) * | 2009-04-29 | 2011-11-18 | Rexahn Pharmaceuticals Inc | Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos. |
| CN107811985B (zh) * | 2016-09-13 | 2021-05-28 | 四川科瑞德制药股份有限公司 | 一种抗癫痫缓释制剂及其制备方法与用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL72381A (en) * | 1983-07-20 | 1988-03-31 | Sanofi Sa | Pharmaceutical composition based on valproic acid |
| US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| DE3809764A1 (de) * | 1988-03-23 | 1989-10-05 | Knoll Ag | Mischung aus alginaten und polyacrylaten und deren verwendung |
| FR2643556B1 (fr) * | 1989-02-27 | 1993-03-05 | Sanofi Sa | Composition pharmaceutique a liberation prolongee d'acide valproique |
| US5102668A (en) * | 1990-10-05 | 1992-04-07 | Kingaform Technology, Inc. | Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH |
| WO1997006787A2 (en) * | 1995-08-17 | 1997-02-27 | Dyer, Alison, Margaret | Controlled release products |
| AUPN969796A0 (en) * | 1996-05-07 | 1996-05-30 | F.H. Faulding & Co. Limited | Taste masked liquid suspensions |
| US6204255B1 (en) * | 1997-03-11 | 2001-03-20 | Hexal Ag | Solid, non-deliquescent formulations of sodium valproate |
-
2000
- 2000-01-26 ES ES00904586T patent/ES2321908T3/es not_active Expired - Lifetime
- 2000-01-26 PT PT00904586T patent/PT1146864E/pt unknown
- 2000-01-26 EP EP00904586A patent/EP1146864B1/en not_active Expired - Lifetime
- 2000-01-26 AT AT00904586T patent/ATE424191T1/de active
- 2000-01-26 WO PCT/US2000/001954 patent/WO2000045793A1/en not_active Ceased
- 2000-01-26 DE DE60041691T patent/DE60041691D1/de not_active Expired - Lifetime
- 2000-01-26 JP JP2000596913A patent/JP5420126B2/ja not_active Expired - Lifetime
- 2000-01-26 DK DK00904586T patent/DK1146864T3/da active
- 2000-01-26 CA CA2361496A patent/CA2361496C/en not_active Expired - Fee Related
-
2009
- 2009-03-06 CY CY20091100254T patent/CY1108863T1/el unknown
-
2011
- 2011-05-24 JP JP2011116089A patent/JP5420590B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2527432B2 (ja) | 持効性ドラッグデリバリ―マトリックスシステム | |
| US5912013A (en) | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine | |
| JP2763879B2 (ja) | 徐放性カプセルもしくは錠剤製剤及びその調製方法 | |
| JPH02240017A (ja) | 放出性が改良されたジエムフイブロジル組成物 | |
| WO2001035958A1 (en) | Carvedilol methanesulfonate | |
| KR20040037026A (ko) | 심장병 및 순환성 질병을 치료하고 예방하기 위한 하루1회 요법용 제어방출형 경구 약제학적 조성물 | |
| CN1151778C (zh) | 含有恩他卡朋和硝替卡朋以及交联纤维素衍生物的药物组合物 | |
| JP2008503475A5 (enExample) | ||
| MX2007008162A (es) | Formulaciones farmaceuticas de liberacion prolongada que contienen ranolazina. | |
| JP2011241218A5 (enExample) | ||
| JP2011241218A (ja) | ｐＨ非依存延長放出性医薬組成物 | |
| JP2003525223A (ja) | イブプロフェンを含有する活性成分製剤 | |
| JP2002536318A5 (enExample) | ||
| US6150410A (en) | pH independent extended release pharmaceutical formulation | |
| WO2001076562A1 (en) | A peroral pharmaceutical formulation for controlled release of a drug | |
| JPH0757726B2 (ja) | 高分子量ヒドロキシプロピルメチルセルロースを基剤にした徐放性錠剤 | |
| EP1496868A1 (en) | Controlled release pharmaceutical compositions of carbidopa and levodopa | |
| WO2008101375A1 (en) | A gastric retentive sustained-release pharmaceutical composition comprising irbesartan | |
| US20060210625A1 (en) | Sustained release of positively charged pharmacologically active molecules from a matrix containing polymers with polarized oxygen atoms | |
| WO2009040388A1 (en) | Controlled release tamsulosin hydrochloride tablets and a process of making them | |
| WO2003030920A1 (en) | An antispasmodic agent spaced drug delivery system | |
| EP1510205B1 (en) | Universal controlled-release composition comprising xanthan gum and sodium alginate | |
| US20040228918A1 (en) | Granule modulating hydrogel system | |
| WO2006011001A2 (en) | Controlled release compositions of divalproex sodium | |
| HK1019203A (en) | Pharmaceutical formulations |